secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001999371-26-006915
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix doses first participant in Phase 1 study of TNX-1900 for migraine and craniofacial pain
--------------------------------------------------------------------------------

- First participant dosed in Phase 1 investigator-initiated study of TNX-1900 (intranasal potentiated oxytocin).
- Study evaluates effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation in healthy female volunteers.
- Principal investigator Dr. Antoinette Maassen van den Brink, Erasmus University Medical Center.
- TNX-1900 targets a distinct pathway from CGRP inhibitors and triptans, blocking CGRP release in animal models.
- Use of Laser Speckle Contrast Imaging (LSCI) for real-time dermal blood flow measurements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126006915/0001999371-26-006915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126006915/tnxp-8k_032526.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-006915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer